A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143) (Q83139270)

From Wikidata

Jump to navigation Jump to search

scientific article published on 06 March 2010

Language	Label	Description	Also known as
English	A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)	scientific article published on 06 March 2010

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20204674%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143) (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20204674%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

colorectal cancer

1 reference

based on heuristic

inferred from title

author name string

José María Viéitez

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20204674%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Manuel Valladares

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20204674%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Ignacio Peláez

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20204674%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Luis de Sande González

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20204674%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Jesús García-Foncillas

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20204674%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

José Luis García-López

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20204674%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Carlos García-Girón

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20204674%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Margarita Reboredo

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20204674%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Humberto Bovio

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20204674%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Angel Jiménez Lacave

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20204674%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

6 March 2010

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20204674%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Investigational New Drugs

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20204674%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

29

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20204674%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1038-1044

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20204674%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20204674%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

https://scigraph.springernature.com/pub.10.1007/s10637-010-9400-z

0 references

Clinical management of cutaneous toxicity of anti-EGFR agents.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Integration of the anti-EGFR agent panitumumab into clinical practice in metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Novel targets for anticancer treatment development in colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab: clinical results in colorectal cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mature results from three large controlled studies with raltitrexed ('Tomudex').

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Raltitrexed, a new drug for advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab for the treatment of colorectal cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

‘Tomudex’ (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Irinotecan in the treatment of advanced colorectal cancer in patients pretreated with Fluorouracil-based chemotherapy: a study to determine recommendable therapeutic dosage

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New approaches in systemic treatment of advanced colorectal cancer: the molecular targets era.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one?

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204674

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83139270&oldid=1405488365"